SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Sepracor-Looks very promising
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Thomas M. who wrote (916)6/22/1998 4:16:00 PM
From: Biomaven  Read Replies (1) of 10280
 
Here's a snippet on the oral version of levalbuterol, courtesy a Labopharm release:

A fourth project is slated for clinical development in the near future. It is part of the agreement with Sepracor in the U.S., under which the two companies are jointly developing solid oral dosage forms of levalbuterol (R-albuterol) using Contramid(R) technology. Levalbuterol is a patented ''Improved Chemical Entity'' (ICE(TM)) for the treatment of asthma. It has the potential to offer improvements over albuterol, which is marketed as Ventolin(R)(i) and Proventil(R)(i). An NDA with the Food and Drug Administration (FDA) for approval of this drug in nebulizer form was filed in July, 1997. Clinical development of the solid oral dosage form is expected to take approximately two years. The potential market for the product in solid oral dosage form is estimated at between $200 and $500 million.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News